MBX Biosciences eases after stock offering announced

** Shares of MBX Biosciences MBX.O down 4.5% at $19.11 on Tues as co looks to raise equity after its stock doubled in prior session

** MBX shares on Mon closed up 100% at $20 after co said its experimental drug, canvuparatide, met main goal in mid-stage trial for adults with chronic hypoparathyroidism, a hormone disorder that causes low calcium levels

** After the bell, Carmel, Indiana-based MBX announced 10 million share offering

** W ith ~33.6 mln shares outstanding, co has about $640 mln market cap

** JP Morgan, Jefferies, TD Cowen and Guggenheim are joint bookrunners for the offering

** Separately, Oppenheimer hiked its PT from $38 to $80

** Avg rating among 7 analysts covering MBX is "strong buy" and median PT is $45, per LSEG data

** MBX went public last Sept after IPO of 10.2 mln shares priced at $16